CareDx (CDNA)
(Delayed Data from NSDQ)
$8.23 USD
+0.19 (2.36%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.23 USD
+0.19 (2.36%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $8.22 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Zacks News
Tenet Healthcare's (THC) Earnings Beat in Q3, Improve Y/Y
by Zacks Equity Research
Tenet Healthcare's (THC) third-quarter earnings gain from the Ambulatory segment and lower expenses.
UnitedHealth's (UNH) Earnings in Q3 Beat on Higher Revenues
by Zacks Equity Research
UnitedHealth's (UNH) Q3 earnings top estimates on solid revenues but the same was down year over year as health care utilization is resuming normalcy.
Here's Why CareDx (CDNA) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
What's in the Offing for UnitedHealth (UNH) Earnings in Q3?
by Zacks Equity Research
UnitedHealth's (UNH) Q3 results are likely to reflect a rise in revenues but a decline in earnings.
CareDx (CDNA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 166.67% and 17.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Cigna (CI) Keep the Beat Streak Alive in Q2 Earnings?
by Zacks Equity Research
Cigna's (CI) business is likely to have been weighed down in Q2 due to high unemployment rate, partly offset by the delay in elective procedures resulting in lower claims.
5 Healthcare Stocks to Beat on Q2 Earnings Despite Coronavirus
by Zacks Equity Research
Companies across the healthcare sector experience a mixed impact from coronavirus. While some gain traction from a surge in virtual care, the rest suffers demand woes and supply-chain glitches.
CareDx (CDNA) Reports Break-Even Earnings for Q1
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -100.00% and 0.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CareDx (CDNA) Q1 Earnings Expected to Decline
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in CareDx (CDNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to CareDx (CDNA) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
Trump Mulling Tax Cuts to Incentivize Stock Buying? 6 Picks
by Nalak Das
President Trump's tenure has seen Wall Street perform exceptionally well so far. In fact, Trump often cites Wall Street's bull run as a reflection of his good governance.
CareDx (CDNA) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
CareDx (CDNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
US Service Sector Accelerates in January: 5 Stocks to Buy
by Zacks Equity Research
U.S. service sector and job market are flourishing, per January's ISM's non-manufacturing report. Investors can make the most by investing in the top-performing sectors.
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
5 Defensive Stocks to Counter Coronavirus Scare
by Zacks Equity Research
Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.
Super Bowl Results Show Stock Gains in February: 5 Picks
by Tirthankar Chakraborty
Markets have done well in years when AFL teams have won the Super Bowl than in years when the victors are from the NFL. With the Kansas City Chiefs winning this year, we can expect stocks to climb.
Teladoc (TDOC) Hits 52-Week High: Will Momentum Sustain?
by Sapna Bagaria
Teladoc (TDOC) stock gains from from positive earnings pre-announcement and news to acquire InTouch Health.
All You Need to Know About CareDx (CDNA) Rating Upgrade to Strong Buy
by Zacks Equity Research
CareDx (CDNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top Ranked Momentum Stocks to Buy for October 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 18th
CareDx, Inc (CDNA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in CareDx, Inc (CDNA).
CareDx (CDNA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Trump's Kidney Disease Executive Order May Boost This Health Stock, Tank Others
by Mitchell Moore
President Trump signed an executive order Wednesday that will encourage an increase in kidney transplants. This transplant diagnostic company stands to grow significantly, while dialysis companies will take a hit.
CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 350.00% and 7.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.